文献速递临床试验与 GCP

可穿戴低强度脉冲超声治疗帕金森病运动障碍的疗效(SWUMP试验):单中心、双盲、随机对照试验方案

Efficacy of Wearable low-intensity pulsed Ultrasound treatment in the Movement disorder in Parkinson's disease (the SWUMP trial): protocol for a single-site, double-blind, randomized controlled trial.
PubMed 文献 · Trials · 2024-04-22

SWUMP试验为单中心、前瞻性、双盲随机对照试验,拟纳入48例临床确诊的帕金森病患者,随机分为低强度脉冲超声(LIPUS)组与假刺激组,所有参与者继续接受药物治疗。主要结局为基线至4个月统一帕金森病评定量表(UPDRS)第三部分运动评分变化的组间差异,同时评估认知量表、高密度脑电图与功能磁共振成像等指标及安全性。

要点

  • LIPUS在帕金森病动物模型中可改善行为功能,兼具无创性与高空间精度。
  • 主要结局为基线至4个月UPDRS第三部分运动评分变化的组间差异。
  • 若LIPUS有效,可借助可穿戴设备在家庭环境中拓展超声治疗的可及性。

核心结论

  • 本研究首次对治疗性LIPUS治疗帕金森病的疗效开展临床研究;若LIPUS被判定有效,可借助可穿戴LIPUS设备在家庭环境中提供实用且创新的途径以拓展超声治疗的可及性。

研究设计与样本

  • 单中心、前瞻性、双盲、随机对照试验,拟纳入48例临床确诊的帕金森病患者,随机分配至LIPUS组或假刺激组,所有参与者继续以药物治疗为基本治疗。

主要发现

  • 主要结局为基线至4个月统一帕金森病评定量表(UPDRS)第三部分运动评分变化的组间差异。

关键数值与推荐

  • 次要结局包括简易精神状态检查(MMSE)等评定量表及其他三项评定量表,以及高密度脑电图(hdEEG)和功能磁共振成像(fMRI)等医学检查;主要安全性结局在4个月时评估,并记录不良事件。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parkinson's disease (PD) is a progressive, neurodegenerative illness marked by the loss of dopaminergic neurons, causing motor symptoms. Oral levodopa replacement therapy remains the gold standard in the treatment of PD. It is, nevertheless, a symptomatic treatment. There is currently no effective treatment for PD. Therefore, new therapies for PD are highly desirable. Low-intensity pulsed ultrasound (LIPUS) has been shown to improve behavioral functions in PD animal models. It is a new type of neuromodulation approach that combines noninvasiveness with high spatial precision. The purpose of this study is to establish a new clinical protocol for LIPUS in the treatment of movement disorders in patients with PD. METHODS: This protocol is a single-site, prospective, double-blind, randomized controlled trial (RCT). Forty-eight participants with clinically confirmed PD will be randomly allocated to one of two groups: LIPUS group or sham group. All of the participants continue to use pharmacological therapy as a fundamental treatment. The primary outcome is the difference between groups from baseline to 4 months in the change in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score (part III). The secondary outcomes include the rating scales such as the Mini-Mental State Examination (MMSE), and other three rating scales, and medical examinations including high-density electroencephalography (hdEEG) and functional magnetic resonance imaging (fMRI). The primary safety outcome will be assessed at 4 months, and adverse events will be recorded. DISCUSSION: This study represents the clinical investigation into the efficacy of therapeutic LIPUS in the treatment of PD for the first time. If LIPUS is determined to be effective, it could offer a practical and innovative means of expanding the accessibility of ultrasound therapy by using a wearable LIPUS device within a home setting. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100052093. Registered on 17 October 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhong C, Guo N, Hu C, et al. Efficacy of Wearable low-intensity pulsed Ultrasound treatment in the Movement disorder in Parkinson's disease (the SWUMP trial): protocol for a single-site, double-blind, randomized controlled trial. Trials. 2024. PMID: 38650028. doi:10.1186/s13063-024-08092-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。